LOGIN
Combined parathyroid hormone+alendronate therapy versus PTH monotherpy for osteoporosis
March 2016
Combined parathyroid hormone+alendronate therapy versus PTH monotherpy for osteoporosis
Study Type:Meta analysis
OE Level Evidence:1
Journal Level of Evidence:N/A
Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
J Invest Surg. 2015 Dec;28(6):309-16Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
6 randomized controlled trials, including a total of 833 patients, were analyzed to evaluate the efficacy of combined parathyroid hormone (PTH) and alendronate administration in the treatment of osteoporosis. The meta-analysis assessed mean percent increases in bone mineral density (BMD) at the lumbar spine, femoral neck, total hip, and distal radius with combination therapy compared to monothera...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.